

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/GE BDF36D74E6EN.html>

Date: February 2023

Pages: 103

Price: US\$ 3,660.00 (Single User License)

ID: GE BDF36D74E6EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

RIMAs are used as antidepressants. They work by reducing the activity of monoamine oxidase which is a chemical found throughout the body. Monoamine oxidase breaks down noradrenaline (also called norepinephrine) and serotonin and other chemicals made and used by the body and brain. These chemicals are important in emotions and depression.

LPI (LP Information)' newest research report, the "Reversible Inhibitors of Monoamine (RIMA) Antidepressants Industry Forecast" looks at past sales and reviews total world Reversible Inhibitors of Monoamine (RIMA) Antidepressants sales in 2022, providing a comprehensive analysis by region and market sector of projected Reversible Inhibitors of Monoamine (RIMA) Antidepressants sales for 2023 through 2029. With Reversible Inhibitors of Monoamine (RIMA) Antidepressants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Reversible Inhibitors of Monoamine (RIMA) Antidepressants industry.

This Insight Report provides a comprehensive analysis of the global Reversible Inhibitors of Monoamine (RIMA) Antidepressants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Reversible Inhibitors of Monoamine (RIMA) Antidepressants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Reversible Inhibitors of Monoamine (RIMA) Antidepressants and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Reversible Inhibitors of Monoamine (RIMA) Antidepressants.

The global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Reversible Inhibitors of Monoamine (RIMA) Antidepressants is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Reversible Inhibitors of Monoamine (RIMA) Antidepressants is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Reversible Inhibitors of Monoamine (RIMA) Antidepressants is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Reversible Inhibitors of Monoamine (RIMA) Antidepressants players cover Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly & Co., GlaxoSmithKline Plc, H. Lundbeck, Merck, Pfizer and Teva Pharmaceutical Industries Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Reversible Inhibitors of Monoamine (RIMA) Antidepressants market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Nonselective MAO-A inhibitors

Selective MAO-B inhibitors

Nonselective MAO-B inhibitors

Segmentation by application

Depression Treatment

Parkinson's Disease Treatment

Other Therapy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Alkermes Plc

Allergan Plc

Bristol Myers Squibb Co.

Eli Lilly & Co.

GlaxoSmithKline Plc

H. Lundbeck

Merck

Pfizer

Teva Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2018-2029

2.1.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Region 2018 VS 2022 VS 2029

2.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Segment by Type

2.2.1 Nonselective MAO-A inhibitors

2.2.2 Selective MAO-B inhibitors

2.2.3 Nonselective MAO-B inhibitors

2.3 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type

2.3.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Type (2018 VS 2022 VS 2029)

2.3.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

2.4 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Segment by Application

2.4.1 Depression Treatment

2.4.2 Parkinson's Disease Treatment

2.4.3 Other Therapy

2.5 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application

2.5.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Application (2018 VS 2022 VS 2029)

2.5.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size

Market Share by Application (2018-2023)

3 REVERSIBLE INHIBITORS OF MONOAMINE (RIMA) ANTIDEPRESSANTS MARKET SIZE BY PLAYER

3.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Players

3.1.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue by Players (2018-2023)

3.1.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Players (2018-2023)

3.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 REVERSIBLE INHIBITORS OF MONOAMINE (RIMA) ANTIDEPRESSANTS BY REGIONS

4.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions (2018-2023)

4.2 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth (2018-2023)

4.3 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth (2018-2023)

4.4 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth (2018-2023)

4.5 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2018-2023)

5.2 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023)

5.3 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2018-2023)

6.2 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023)

6.3 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants by Country (2018-2023)

7.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023)

7.3 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants by

Region (2018-2023)

8.2 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants

Market Size by Type (2018-2023)

8.3 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants

Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL REVERSIBLE INHIBITORS OF MONOAMINE (RIMA) ANTIDEPRESSANTS MARKET FORECAST

10.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Regions (2024-2029)

10.1.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Regions (2024-2029)

10.1.2 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast

10.1.3 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast

10.1.4 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast

10.1.5 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Forecast

10.2 Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Country (2024-2029)

10.2.1 United States Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.2.2 Canada Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.2.3 Mexico Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.2.4 Brazil Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3 APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Region (2024-2029)

10.3.1 China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3.2 Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3.3 Korea Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3.4 Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3.5 India Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.3.6 Australia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.4 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Country (2024-2029)

10.4.1 Germany Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.4.2 France Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.4.3 UK Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.4.4 Italy Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.4.5 Russia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.5 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Region (2024-2029)

10.5.1 Egypt Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.5.2 South Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.5.3 Israel Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.5.4 Turkey Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.5.5 GCC Countries Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Forecast

10.6 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by

Type (2024-2029)

10.7 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Alkermes Plc

11.1.1 Alkermes Plc Company Information

11.1.2 Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

11.1.3 Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)

11.1.4 Alkermes Plc Main Business Overview

11.1.5 Alkermes Plc Latest Developments

11.2 Allergan Plc

11.2.1 Allergan Plc Company Information

11.2.2 Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

11.2.3 Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)

11.2.4 Allergan Plc Main Business Overview

11.2.5 Allergan Plc Latest Developments

11.3 Bristol Myers Squibb Co.

11.3.1 Bristol Myers Squibb Co. Company Information

11.3.2 Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

11.3.3 Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)

11.3.4 Bristol Myers Squibb Co. Main Business Overview

11.3.5 Bristol Myers Squibb Co. Latest Developments

11.4 Eli Lilly & Co.

11.4.1 Eli Lilly & Co. Company Information

11.4.2 Eli Lilly & Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

11.4.3 Eli Lilly & Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)

11.4.4 Eli Lilly & Co. Main Business Overview

11.4.5 Eli Lilly & Co. Latest Developments

11.5 GlaxoSmithKline Plc

- 11.5.1 GlaxoSmithKline Plc Company Information
- 11.5.2 GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered
- 11.5.3 GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 GlaxoSmithKline Plc Main Business Overview
- 11.5.5 GlaxoSmithKline Plc Latest Developments
- 11.6 H. Lundbeck
 - 11.6.1 H. Lundbeck Company Information
 - 11.6.2 H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered
 - 11.6.3 H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 H. Lundbeck Main Business Overview
 - 11.6.5 H. Lundbeck Latest Developments
- 11.7 Merck
 - 11.7.1 Merck Company Information
 - 11.7.2 Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered
 - 11.7.3 Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Merck Main Business Overview
 - 11.7.5 Merck Latest Developments
- 11.8 Pfizer
 - 11.8.1 Pfizer Company Information
 - 11.8.2 Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered
 - 11.8.3 Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Pfizer Main Business Overview
 - 11.8.5 Pfizer Latest Developments
- 11.9 Teva Pharmaceutical Industries Ltd.
 - 11.9.1 Teva Pharmaceutical Industries Ltd. Company Information
 - 11.9.2 Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered
 - 11.9.3 Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
 - 11.9.5 Teva Pharmaceutical Industries Ltd. Latest Developments

11.10 Takeda Pharmaceutical Co. Ltd.

11.10.1 Takeda Pharmaceutical Co. Ltd. Company Information

11.10.2 Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

11.10.3 Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue, Gross Margin and Market Share (2018-2023)

11.10.4 Takeda Pharmaceutical Co. Ltd. Main Business Overview

11.10.5 Takeda Pharmaceutical Co. Ltd. Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Nonselective MAO-A inhibitors

Table 3. Major Players of Selective MAO-B inhibitors

Table 4. Major Players of Nonselective MAO-B inhibitors

Table 5. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 6. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023) & (\$ Millions)

Table 7. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Table 8. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 9. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023) & (\$ Millions)

Table 10. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application (2018-2023)

Table 11. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue by Players (2018-2023) & (\$ Millions)

Table 12. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Player (2018-2023)

Table 13. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Key Players Head office and Products Offered

Table 14. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions 2018-2023 & (\$ Millions)

Table 18. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Regions (2018-2023)

Table 19. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue by Country/Region (2018-2023) & (\$ millions)

Table 20. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Country/Region (2018-2023)

Table 21. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2018-2023) & (\$ Millions)

Table 22. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Country (2018-2023)

Table 23. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023) & (\$ Millions)

Table 24. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Table 25. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023) & (\$ Millions)

Table 26. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application (2018-2023)

Table 27. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2018-2023) & (\$ Millions)

Table 28. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Region (2018-2023)

Table 29. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023) & (\$ Millions)

Table 30. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Table 31. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023) & (\$ Millions)

Table 32. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application (2018-2023)

Table 33. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2018-2023) & (\$ Millions)

Table 34. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Country (2018-2023)

Table 35. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2018-2023) & (\$ Millions)

Table 36. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Table 37. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2018-2023) & (\$ Millions)

Table 38. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application (2018-2023)

Table 39. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2018-2023) & (\$ Millions)

Table 40. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Market Size Market Share by Region (2018-2023)

Table 41. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Market Size by Type (2018-2023) & (\$ Millions)

Table 42. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Market Size Market Share by Type (2018-2023)

Table 43. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Market Size by Application (2018-2023) & (\$ Millions)

Table 44. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA)

Antidepressants Market Size Market Share by Application (2018-2023)

Table 45. Key Market Drivers & Growth Opportunities of Reversible Inhibitors of Monoamine (RIMA) Antidepressants

Table 46. Key Market Challenges & Risks of Reversible Inhibitors of Monoamine (RIMA) Antidepressants

Table 47. Key Industry Trends of Reversible Inhibitors of Monoamine (RIMA) Antidepressants

Table 48. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 49. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share Forecast by Regions (2024-2029)

Table 50. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 51. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 52. Alkermes Plc Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 53. Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 54. Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 55. Alkermes Plc Main Business

Table 56. Alkermes Plc Latest Developments

Table 57. Allergan Plc Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 58. Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 59. Allergan Plc Main Business

Table 60. Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 61. Allergan Plc Latest Developments

Table 62. Bristol Myers Squibb Co. Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 63. Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 64. Bristol Myers Squibb Co. Main Business

Table 65. Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 66. Bristol Myers Squibb Co. Latest Developments

Table 67. Eli Lilly & Co. Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 68. Eli Lilly & Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 69. Eli Lilly & Co. Main Business

Table 70. Eli Lilly & Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 71. Eli Lilly & Co. Latest Developments

Table 72. GlaxoSmithKline Plc Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 73. GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 74. GlaxoSmithKline Plc Main Business

Table 75. GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 76. GlaxoSmithKline Plc Latest Developments

Table 77. H. Lundbeck Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 78. H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 79. H. Lundbeck Main Business

Table 80. H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 81. H. Lundbeck Latest Developments

Table 82. Merck Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 83. Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 84. Merck Main Business

Table 85. Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 86. Merck Latest Developments

Table 87. Pfizer Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 88. Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 89. Pfizer Main Business

Table 90. Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 91. Pfizer Latest Developments

Table 92. Teva Pharmaceutical Industries Ltd. Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 93. Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 94. Teva Pharmaceutical Industries Ltd. Main Business

Table 95. Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 96. Teva Pharmaceutical Industries Ltd. Latest Developments

Table 97. Takeda Pharmaceutical Co. Ltd. Details, Company Type, Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served and Its Competitors

Table 98. Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Offered

Table 99. Takeda Pharmaceutical Co. Ltd. Main Business

Table 100. Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 101. Takeda Pharmaceutical Co. Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Sales Market Share by Country/Region (2022)

Figure 8. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type in 2022

Figure 10. Reversible Inhibitors of Monoamine (RIMA) Antidepressants in Depression Treatment

Figure 11. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market: Depression Treatment (2018-2023) & (\$ Millions)

Figure 12. Reversible Inhibitors of Monoamine (RIMA) Antidepressants in Parkinson's Disease Treatment

Figure 13. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market: Parkinson's Disease Treatment (2018-2023) & (\$ Millions)

Figure 14. Reversible Inhibitors of Monoamine (RIMA) Antidepressants in Other Therapy

Figure 15. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market: Other Therapy (2018-2023) & (\$ Millions)

Figure 16. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application in 2022

Figure 17. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Player in 2022

Figure 18. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Value Market Share by Country in 2022

Figure 24. United States Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Region in 2022

Figure 29. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type in 2022

Figure 30. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application in 2022

Figure 31. China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Country in 2022

Figure 38. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Figure 39. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market

Size Market Share by Application (2018-2023)

Figure 40. Germany Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Italy Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 57. United States Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 61. China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 65. India Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 68. France Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 69. UK Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size 2024-2029 (\$ Millions)

Figure 78. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market

Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market

Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/GEbDF36D74E6EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEbDF36D74E6EN.html>